Inhibitor Therapeutics Inc (INTI):企業の財務・戦略的SWOT分析

◆英語タイトル:Inhibitor Therapeutics Inc (INTI) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH496811FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Inhibitor Therapeutics Inc (INTI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Inhibitor Therapeutics Inc (Inhibitor) formerly known as Hedgepath Pharmaceuticals Inc, a subsidiary of Mayne Pharma Group Ltd, is a clinical stage biopharmaceutical company that discovers, develops and commercializes novel therapeutics for the treatment of prostrate, and lung cancers. The company is investigating an oral formulation of Itraconazole in phase 2b clinical trials for the treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome. It employs super bioavailability technology (SUBA), a novel drug delivery technology that improves the bioavailability of orally administered drugs which have limited solubility. The company holds an exclusive licensee for Mayne Pharma Group’s SUBA-Itraconazole. Inhibitor is headquartered in Tampa, Florida, the US.

Inhibitor Therapeutics Inc Key Recent Developments

May 03,2020: Inhibitor Therapeutics receives loan under Paycheck Protection Program

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Inhibitor Therapeutics Inc – Key Facts
Inhibitor Therapeutics Inc – Key Employees
Inhibitor Therapeutics Inc – Key Employee Biographies
Inhibitor Therapeutics Inc – Major Products and Services
Inhibitor Therapeutics Inc – History
Inhibitor Therapeutics Inc – Company Statement
Inhibitor Therapeutics Inc – Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
Inhibitor Therapeutics Inc – Business Description
R&D Overview
Inhibitor Therapeutics Inc – Corporate Strategy
Inhibitor Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Inhibitor Therapeutics Inc – Strengths
Inhibitor Therapeutics Inc – Weaknesses
Inhibitor Therapeutics Inc – Opportunities
Inhibitor Therapeutics Inc – Threats
Inhibitor Therapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 03, 2020: Inhibitor Therapeutics receives loan under Paycheck Protection Program
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Inhibitor Therapeutics Inc, Key Facts
Inhibitor Therapeutics Inc, Key Employees
Inhibitor Therapeutics Inc, Key Employee Biographies
Inhibitor Therapeutics Inc, Major Products and Services
Inhibitor Therapeutics Inc, History
Inhibitor Therapeutics Inc, Key Competitors
Inhibitor Therapeutics Inc, Ratios based on current share price
Inhibitor Therapeutics Inc, Annual Ratios
Inhibitor Therapeutics Inc, Annual Ratios (Cont...1)
Inhibitor Therapeutics Inc, Interim Ratios
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Inhibitor Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Inhibitor Therapeutics Inc (INTI):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • RigNet Inc (RNET):企業の財務・戦略的SWOT分析
    RigNet Inc (RNET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Galapagos NV (GLPG):製薬・医療:M&Aディール及び事業提携情報
    Summary Galapagos NV (Galapagos) is a biotechnology company that discovers and develops small molecule medicines. The company’s clinical pipeline include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn’s disease, Phase 2 and 3 trials for ulcerati …
  • First Republic Bank:企業のM&A・事業提携・投資動向
    First Republic Bank - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's First Republic Bank Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Hunan Corun New Energy Co Ltd (600478)-エネルギー分野:企業M&A・提携分析
    Summary Hunan Corun New Energy Co Ltd (Corun) is a battery manufacturing company that designs, research's, produces and commercializes materials and batteries. The company develops high quality energy materials, extension products and advanced batteries. It also manufactures ultra-intense bonding ni …
  • Oncodesign SA (ALONC):企業の財務・戦略的SWOT分析
    Summary Oncodesign SA (Oncodesign) is a biopharmaceutical company, specializing in precision medicine offers drug discovery and pharmacological evaluation services for cancer. Its service offerings include integrated drug discovery; metabolic and pharmacokinetic characteristics of chemical and biolo …
  • National Bank of Kuwait SAK:企業の戦略・SWOT・財務情報
    National Bank of Kuwait SAK - Strategy, SWOT and Corporate Finance Report Summary National Bank of Kuwait SAK - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Daepyung Co., Ltd.:戦略・SWOT・企業財務分析
    Daepyung Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daepyung Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Blue Label Telecoms Ltd (BLU):企業の財務・戦略的SWOT分析
    Blue Label Telecoms Ltd (BLU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Al Arrab Contracting Company:企業の戦略的SWOT分析
    Al Arrab Contracting Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Al Mouwasat Medical Services Company (4002):企業の財務・戦略的SWOT分析
    Summary Al Mouwasat Medical Services Company (Mouwasat Medical) is a healthcare service provider that provides health and skincare services. The centre offers services in health care, skin care, and fertility treatment. It provides clinical pharmacy services such as verifying dosages appropriateness …
  • Nelnet, Inc.:企業の戦略・SWOT・財務情報
    Nelnet, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nelnet, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • A.P. Moller – Maersk AS Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    A.P. Moller - Maersk AS Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary A.P. Moller - Maersk AS (APM) is an integrated transport and logistics company with operations in container shipping and ports operating through a subsidiary and affiliates. It transports dry …
  • Idera Pharmaceuticals Inc (IDRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Idera Pharmaceuticals Inc. (Idera) is a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of drugs for the treatment of cancer and rare diseases. It develops DNA and RNA based drug candidates aimed at toll-like receptors (TLR) for the …
  • PT. Indonesia Power:企業の戦略的SWOT分析
    PT. Indonesia Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Genesis Energy LP (GEL):企業の財務・戦略的SWOT分析
    Genesis Energy LP (GEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • TransGlobe Energy Corp (TGL):企業の財務・戦略的SWOT分析
    Summary TransGlobe Energy Corp (TransGlobe Energy) is an oil and gas company that explores, develops and produces crude oil and natural gas. The company develops oil and natural gas properties in the Arab Republic of Egypt and the Republic of Yemen. It holds interests in various production sharing c …
  • Genmab AS (GMAB):企業の財務・戦略的SWOT分析
    Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Chico’s FAS Inc:企業の戦略・SWOT・財務情報
    Chico's FAS Inc - Strategy, SWOT and Corporate Finance Report Summary Chico's FAS Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Wake Forest Innovations-製薬・医療分野:企業M&A・提携分析
    Summary Wake Forest Innovations (Wake Forest), a subsidiary of Wake Forest Baptist Medical Center, is an enterprise that advances the development and commercialization of discoveries; services; and products such as medicines and vaccines, from the Medical Center and Wake Forest University. The compa …
  • BayWa AG:戦略・SWOT・企業財務分析
    BayWa AG - Strategy, SWOT and Corporate Finance Report Summary BayWa AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆